Valeritas (NSDQ:VLRX) touted positive findings today from an analysis of its V-Go wearable insulin delivery system with a weekly physician-driven insulin titration algorithm. Two-thirds of patients met their glycemic targets, the company said, and patient-reported hypoglycemia dropped by the end of the study. In adult patients with Type II diabetes prescribed V-Go, daily self-monitored blood glucose […]
Diabetes
Insulet raises full-year sales forecast after Street-beating Q3
Shares in Insulet (NSDQ:PODD) soared today after the medical device maker topped sales expectations on Wall Street with its third quarter results. The Billerica, Mass-based company posted a net loss of -$2.2 million on sales of $121.8 million for the 3 months ended Sept. 30, for bottom-line growth of 38% on sales growth of 28% compared […]
Dexcom beats earnings estimate by 12 cents in Q3
Shares in Dexcom (NSDQ:DXCM) soared today after the medical device maker topped expectations on Wall Street with its third quarter results. The San Diego, Calif.-based company posted a net loss of -$2 million, or -2¢ per share, on sales of $184.6 million for the 3 months ended Sept. 30, for sales growth of 24% compared with […]
One Drop partners with Fitbit to bring diabetes data to people’s wrists
One Drop announced yesterday that it landed a multi-part collaboration with Fitbit (NYSE:FIT). The group’s first initiative will be to integrate Fitbit’s data onto One Drop’s mobile app for diabetes management, the company said, in the hopes to helping One Drop users better understand how physical activity impacts blood glucose management. The data from Fitbit will […]
Senseonics tops sales estimates with Q3 results
Shares in Senseonics (NYSE:SENS) fell today even though the medical technology company beat expectations on Wall Street with its third quarter results. The Germantown, Md.-based company posted a loss of -$17.4 million on sales of $2.1 million for the 3 months ended Sept. 30. Adjusted to exclude 1-time items, earnings per share were -13¢, in-line […]
Novo Nordisk shares slip on cautious guidance, insulin pricing concerns
Shares in Novo Nordisk (NYSE:NVO) fell slightly today after the insulin-maker met expectations on Wall Street with its third quarter results, but issued cautious sales guidance for 2018. The company’s chief executive expressed concerns that draft legislation to make drug pricing more transparent could potentially hurt the industry, according to Reuters. “If the transparency bills lead to […]
Study: Glooko’s mobile app boosts glycemic control in patients with Type II diabetes
Glooko touted data today from a feasibility study evaluating the impact of its mobile insulin dosing system for people with Type II diabetes who are taking long-acting insulin. The Mountain View, Calif.-based company said it hoped to better understand the extent to which its system can make appropriate insulin titration adjustments and improve a patient’s […]
Tandem reels in losses but misses revenue estimates in Q3
Shares in Tandem Diabetes Care (NSDQ:TNDM) rose today after the medical device maker reeled in its losses but missed sales estimates on Wall Street with its third quarter results. The San Diego, Calif.-based company posted losses of -$16 million on sales of $23.7 million for the 3 months ended Sept. 30, for bottom-line growth of 46% […]
Tandem looks to get in on ex-Animas customer base
Tandem Diabetes Care (NSDQ:TNDM) and Dexcom (NSDQ:DXCM) announced yesterday that the companies would extend their existing joint welcome program aimed at luring Animas customers as Johnson & Johnson (NYSE:JNJ) bails out of the insulin pump biz. Tandem and Dexcom’s t:slim X2 welcome program was slated to end on Dec. 31, but the companies said yesterday that it would continue until […]
Medtronic touts economic analysis of CGM use in Type II diabetes
Medtronic (NYSE:MDT) touted data today from an economic analysis evaluating the use of professional continuous glucose monitoring in people with Type II diabetes. Data from the study, which the company called the first of its kind, showed significant cost avoidance to the healthcare system when CGM was used during a therapy change or when used […]